Latest Coagulation system Stories

Instrumentation Laboratory Launches Fully Automated HemosIL® AcuStar VWF Assay Panel In Europe And International Territories

2013-02-05 08:35:20

BEDFORD, Mass., Feb. 5, 2013 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of their new HemosIL AcuStar von Willebrand Factor (VWF) assay panel as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. The CE IVD Mark allows IL to commence distribution of the product in the European Union and other international territories. The fully automated HemosIL AcuStar VWF assay panel, designed exclusively for use on...

CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B

2013-01-21 08:24:57

KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ -- CSL Behring has announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years). The study site for this first enrollment is the Czech Republic. "CSL continues to advance at a very encouraging rate with...

Phase II Study Indicates that Fibrinogen Concentrate Given as a First-Line Therapy Safely Reduces Need for Transfusion after Aortic Surgery

2012-12-19 08:25:21

MARBURG, Germany, Dec. 19, 2012 /PRNewswire/ -- Clinical study results published today in the journal Anesthesiology showed that human fibrinogen concentrate can significantly reduce the need for blood transfusion when given as an intra-operative, targeted first-line hemostatic therapy in bleeding patients undergoing aortic replacement surgery. The Phase II prospective study, performed by CSL Behring and collaborators at the Hannover Medical School, Germany, enrolled 61...

Sangamo Biosciences Announces Presentation Of Data Demonstrating A Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies At American Society Of Hematology Meeting

2012-12-10 16:24:10

RICHMOND, Calif., Dec. 10, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new pre-clinical data demonstrating the successful application of its In Vivo Protein Replacement Platform. Based on Sangamo's zinc finger DNA-binding protein (ZFP) genome-editing technology, the platform enables the permanent production of therapeutic proteins from the liver with a single systemic treatment, potentially providing curative treatments for a range of...

FDA Approves EVARREST(TM) Fibrin Sealant Patch

2012-12-07 08:24:28

SOMERVILLE, N.J., Dec. 7, 2012 /PRNewswire/ -- Ethicon Biosurgery, Division of Ethicon, Inc., a worldwide leader in hemostasis and sealing solutions, announced today that the U.S. Food and Drug Administration (FDA) has approved EVARREST(TM) Fibrin Sealant Patch, a novel product that rapidly and reliably aids in stopping problematic bleeding during surgery. Unexpected and uncontrollable bleeding during surgery poses a significant challenge to surgeons, and in some surgical...

Bayer Announces Recruitment Achievement for Investigational Hemophilia Treatment

2012-11-28 04:21:19

WAYNE, N.J., Nov. 28, 2012 /PRNewswire/ -- Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete. Recruitment is ongoing at sites located around the world, including in the U.S., where sites are ready to enroll eligible patients. The TRUST trial is designed to evaluate the safety and efficacy of the investigational compound BAY 86-6150, a...

Immunetics, Inc. Names John Yonkin as CEO

2012-11-26 08:25:13

BOSTON, Nov. 26, 2012 /PRNewswire/ -- Immunetics, Inc., an innovative developer of state-of-the-art assay technology for infectious disease diagnosis and blood screening, today announced that the company's Board of Directors has appointed John Yonkin as Chief Executive Officer. Mr. Yonkin will assume the post of CEO effective December 1, 2012. He will also serve as a member of the Board of Directors. Mr. Yonkin brings more than 25 years of business experience in the clinical...

Researchers Reveal Reasons For Severe Bleeding In Hemophilia

2012-11-21 00:17:04

New insights into what causes uncontrollable bleeding in hemophilia patients are provided in a study published by Cell Press on November 20th in the Biophysical Journal. By revealing that blood clots spread in traveling waves through vessels, the study offers new strategies that could lead to the development of more effective treatments for hemophilia as well as common cardiovascular disorders. "Disorders of blood coagulation are a leading and immediate cause of mortality and morbidity in...

Global Anticoagulant Drugs Market & Antithrombotic Drugs Industry Analysis in New Research Reports

2012-11-20 08:25:43

DALLAS, November 20, 2012 /PRNewswire/ -- - RnRMarketResearch.com adds new market research reports "Antithrombotic / Anticoagulant Drugs: Technologies and Global Markets" to its store. This report provides an overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals. Analyses of global market trends, with data from 2011,...

Leaders in Hemophilia Advocacy, Healthcare Delivery and Biotechnology Partner to Offer Free Genetic Testing to People with Hemophilia

2012-11-08 08:35:00

ORLANDO, Fla., Nov. 8, 2012 /PRNewswire/ -- A coalition of leaders in hemophilia advocacy and treatment today announced a nationwide program that will offer free genetic testing to people with hemophilia and their families. The partnership will be officially unveiled this evening at the 64(th) National Hemophilia Foundation (NHF) Annual Meeting in Orlando, Florida. To view the multimedia assets associated with this release, please click:...